Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the rapid growth of abnormal white blood cells called promyelocytes. This condition disrupts the normal production of blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding. APL is often associated with a specific genetic mutation involving the promyelocytic leukemia (PML) gene and the retinoic acid receptor alpha (RARA) gene. Treatment for APL typically involves a combination of chemotherapy and targeted therapy, particularly the use of all-trans retinoic acid (ATRA). ATRA helps to promote the differentiation of the abnormal promyelocytes into mature blood cells, improving patient outcomes. With early diagnosis and appropriate treatment, many